ࡱ> BA  T\pVelisage-10 B=K_8X@"1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1h6 Aptos Narrow1,6 Aptos Narrow16 Aptos Narrow16 Aptos Narrow1< Aptos Narrow1> Aptos Narrow14 Aptos Narrow14 Aptos Narrow1  Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1 Aptos Narrow1? Aptos Narrow1,8 Aptos Narrow18 Aptos Narrow18 Aptos Narrow1< Aptos Narrow1> Aptos Narrow14 Aptos Narrow1  Aptos Narrow1  Aptos Narrow1 Aptos Narrow1 Aptos Narrow1  Aptos Narrow"?"\ #,##0;"?"\ \-#,##0"?"\ #,##0;[Red]"?"\ \-#,##0 "?"\ #,##0.00;"?"\ \-#,##0.00%""?"\ #,##0.00;[Red]"?"\ \-#,##0.00;*8_ "?"\ * #,##0_ ;_ "?"\ * \-#,##0_ ;_ "?"\ * "-"_ ;_ @_ ,))_ * #,##0_ ;_ * \-#,##0_ ;_ * "-"_ ;_ @_ C,@_ "?"\ * #,##0.00_ ;_ "?"\ * \-#,##0.00_ ;_ "?"\ * "-"??_ ;_ @_ 4+1_ * #,##0.00_ ;_ * \-#,##0.00_ ;_ * "-"??_ ;_ @_ "?"#,##0;"?"\-#,##0"?"#,##0;[Red]"?"\-#,##0"?"#,##0.00;"?"\-#,##0.00!"?"#,##0.00;[Red]"?"\-#,##0.0052_ "?"* #,##0_ ;_ "?"* \-#,##0_ ;_ "?"* "-"_ ;_ @_ =:_ "?"* #,##0.00_ ;_ "?"* \-#,##0.00_ ;_ "?"* "-"??_ ;_ @_ \$#,##0_);\(\$#,##0\)\$#,##0_);[Red]\(\$#,##0\)\$#,##0.00_);\(\$#,##0.00\)# \$#,##0.00_);[Red]\(\$#,##0.00\)                                     A.I. + )     A~I~    }| @} @Y  b    A,I,           A.I.     i     20% - ?? 1w 20% - ?? 2w 20% - ?? 3w 20% - ?? 4w 20% - ?? 5w 20% - ?? 6w 40% - ?? 1w 40% - ?? 2w 40% - ?? 3w 40% - ?? 4w 40% - ?? 5w 40% - ?? 6w 60% - ?? 1w 60% - ?? 2w 60% - ?? 3w 60% - ?? 4w 60% - ?? 5w! 60% - ?? 6w"Bad-Bad %# Calculationi Calculation% $ Comma%( Comma [0]&&Currency'. Currency [0](Good/Good a%3Normal % )OutputkOutput ???%????????? ???*$Percent+Title Title,Total1Total % -?? 1?? .?? 2?? /?? 3?? 0?? 4?? 1??????2?? 5 3?? 1?? 4?? 2?? 5?? 3?? 6?? 4?? 7?? 5?? 8?? 6?? 9?????? :??????;????<???? =??????83ffff̙3f3fff3f3f33333f33333RTable S3  T fF,D\\a  dMbP?_*+%,[&ffffff?'ffffff?(?)?"[D S3333333?333333?U f  ? ? , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,Q@ISupplementary Table 3. The results of KEGG analysis in GSE33382 data set.?geneSet? description ?size?overlap?expect?enrichmentRatio?pValue ?FDR?userIdhsa04978Mineral absorptionI@@Rg?%* +@>$z>̦QX?%MT1F;MT1X;MT1A;MT1M;MT2A;MT1Ehsa05219Bladder cancerD@@?#5 @T=u?&q?MAP2K1;CDKN2A;CCND1hsa00450!Selenocompound metabolism1@@`B?%* +@R /?&q?MTR;INMThsa00670!One carbon pool by folate4@@NsL\G?YwF&@;?&q? MTR;MTHFShsa05163'Human cytomegalovirus infection l@@XYT?g}@ima?&q?-%MAP2K1;GNG5;CDKN2A;CCND1;TRAF5;IFNA17hsa05223"Non-small cell lung cancerP@@(Ea?Fn@t?&q?MAP2K1;CDKN2A;CCND1hsa00563>6Glycosylphosphatidylinositol (GPI)-anchor biosynthesis9@@@]`3?{b"@E*$?&q? PIGY;PIGM hsa04917# Prolactin signaling pathway Q@@ smp~? U`β@ *<9P? &q? MAP2K1;SOCS4;CCND1 hsa05214 Glioma Q@@ |'? k@ _u1? &q? MAP2K1;CDKN2A;CCND1 hsa04115 p53 signaling pathway R@@ QE ? ϩk&@  Í? &q? CDKN2A;CCND1;RCHY1 hsa05218 Melanoma R@@ QE ? ϩk&@  Í? &q? MAP2K1;CDKN2A;CCND1 hsa05212 Pancreatic cancer R@@ `ψ? {b@ ފ? &q? MAP2K1;CDKN2A;CCND1hsa05220 Chronic myeloid leukemiaS@@yI1*?雰$@|V<ݜ?&q?MAP2K1;CDKN2A;CCND1hsa04371 Apelin signaling pathway a@@fZ?!3 @h-??P?MAP2K1;GNG5;MEF2D;CCND1hsa04151"PI3K-Akt signaling pathway v@@W@DQo-@O?G #?1)THEM4;MAP2K1;GNG5;MCL1;CCND1;LAMB2;IFNA17hsa05216Thyroid cancerB@@W6Ǜ?(K@ϋ5?'dӉ? MAP2K1;CCND1hsa05222Small cell lung cancer@W@@!(?Ss3R @?f1?CCND1;TRAF5;LAMB2hsa04064$NF-kappa B signaling pathwayW@@t?eu @bQ?f1?BCL10;TRAF5;CFLARhsa04630"JAK-STAT signaling pathway@d@@f?q1 @Lv?f1?SOCS4;MCL1;CCND1;IFNA17hsa01522Endocrine resistanceX@@n ߝJ?X[2@$ @8R?f1?MAP2K1;CDKN2A;CCND1hsa04668TNF signaling pathway[@@y? @RH?~ ?MAP2K1;TRAF5;CFLARhsa05320"Autoimmune thyroid diseaseJ@@6^}?n[4X@ՁSҳ?~ ? TPO;IFNA17hsa051677/Kaposi sarcoma-associated herpesvirus infection@g@@!(?dw@-_?~ ? MAP2K1;GNG5;CCND1;IFNA17hsa04726Serotonergic synapse\@@3 WJ?L@ 3U?~ ?MAP2K1;GNG5;HTR2Ahsa05200Pathways in cancerp@ @OsO@H8g#[?63?~ ?80MAP2K1;GNG5;CDKN2A;CCND1;TRAF5;HES1;LAMB2;IFNA17hsa05213Endometrial cancerM@@h+&? QHܲ@܋X#?~ ? MAP2K1;CCND1hsa04142Lysosome^@@G[u ?pNRk@mc?~ ?AP4M1;NAGLU;AP3B1hsa04370VEGF signaling pathwayM@@^y:n?8 R)@j?ѷ?~ ? MAP2K1;SH2D2Ahsa05169$Epstein-Barr virus infection i@@;?E3K@ ,? , hsa04140  Autophagy `@@ >?  @ X}?~ ? SNAP29;MAP2K1;CFLAR!hsa05162!Measles!`@@!_Ea?!JFn@!^T;q?~ !?!CCND1;RCHY1;IFNA17"hsa03040" Spliceosome"`@@"^Ҁ?"Ec{@"¼`?~ "?"SF3B4;MAGOH;PRPF3#hsa05221#Acute myeloid leukemia#P@@#(Ea?#zٳ= @#⿼?~ #?# MAP2K1;CCND1$hsa051700$(Human immunodeficiency virus 1 infection$j@@$e?$n[4X@$p(Ƽ?~ $? $MAP2K1;GNG5;TRAF5;IFNA17%hsa04210% Apoptosis%a@@%A?%gnNG@%汥S?~ %?%MAP2K1;MCL1;CFLAR&hsa05211&Renal cell carcinoma&@Q@@& C&7?&С/ @&Ns?~ &?& MAP2K1;PRCC'hsa04662)'!B cell receptor signaling pathway'Q@@'|'?'${ @']5?~ '?' MAP2K1;BCL10(hsa05161( Hepatitis B(b@@(QE ?(ġk&@(޵?~ (?(MAP2K1;CCND1;IFNA17)hsa04918!)Thyroid hormone synthesis)R@@)W6Ǜ?)VK@)36X^V?~ )?) SLC5A5;TPO*hsa05224* Breast cancer*`b@@*RYGgw?**@*Ko`?~ *?*MAP2K1;CCND1;HES1+hsa04934+Cushing syndrome+@c@@+2E |q?+ʂ؅^@+GW{0?~ +?+MAP2K1;CDKN2A;CCND1,hsa00100,Steroid biosynthesis,3@?,(J1*?,{z0@,%κ៛?~ ,? ,SQLE-hsa00531%-Glycosaminoglycan degradation-3@?-(J1*?-{z0@-%κ៛?~ -? -NAGLU.hsa04218.Cellular senescence.d@@.ݛwM\G?. t<@.ċ?~ .?.MAP2K1;CDKN2A;CCND1/hsa04217/ Necroptosis/@d@@/f?/^ @/{SRT?~ /?/TRAF5;CFLAR;IFNA170hsa05165&0Human papillomavirus infection00u@@0b@0X?0w?~ 0?&0MAP2K1;CCND1;HES1;LAMB2;IFNA171hsa052101Colorectal cancer1U@@1bS?11`@1~S7?~ 1?1 MAP2K1;CCND12hsa00514,2$Other types of O-glycan biosynthesis26@?2BV?2Fn@2Wk?~ 2? 2POMT13hsa045403 Gap junction3V@@3/U?3JFn@3 O?~ 3?3 MAP2K1;HTR2A4hsa04621+4#NOD-like receptor signaling pathway4e@@4vQd?4ElVj@4s?~ 4?4TRAF5;CARD9;IFNA175hsa05225 5Hepatocellular carcinoma5e@@5vQd?5ElVj@5s?~ 5?5MAP2K1;CDKN2A;CCND16hsa00515*6"Mannose type O-glycan biosynthesis67@?6Xݞ?6\@6Z5W?~ 6? 6POMT17hsa030607Protein export77@?7Xݞ?7\@7Z5W?~ 7?7SEC61G8hsa043608 Axon guidance8e@@8 ^?8UMf}?8BOVN?~ 8?8PLXNA2;EPHB4;EPHA49hsa04950,9$Maturity onset diabetes of the young9:@?9#)e^?9[c@9tW @?~ 9? 9HES1:hsa05152: Tuberculosis:`f@@:Bv?:U:0?:\K?~ :?:BCL10;CARD9;IFNA17;hsa05215;Prostate cancer;@X@@;S?;eAB/@;=n?~ ;?; MAP2K1;CCND1<hsa04660)<!T cell receptor signaling pathway<@Y@@<j!~ ?<4@<pi%?~ <?< MAP2K1;BCL10=hsa04062#=Chemokine signaling pathway=g@@=_(`;Q?=Ѕ3.?=m?~ =?=MAP2K1;GNG5;CCL28>hsa04620,>$Toll-like receptor signaling pathway>Z@@>yd^?>>lc@>N?~ >?> MAP2K1;IFNA17?hsa046250?(C-type lectin receptor signaling pathway?Z@@?yd^??>lc@?N?~ ??? BCL10;CARD9Dl@ ,A ,B ,C ,D ,E ,F ,G ,H ,I ,J ,K ,L ,M ,N ,O ,P ,Q ,R ,S ,T ,U ,V ,W ,X ,Y ,Z ,[ ,\ ,] ,^ ,_ ,@hsa00062@Fatty acid elongation@>@?@چ:?@wy]@@+,?~ @? @THEM4Ahsa03008)A!Ribosome biogenesis in eukaryotesA@Z@@A,%=?ANX~@A^x?~ A?A RIOK2;NVLBhsa04928;B3Parathyroid hormone synthesis, secretion and actionBZ@@B6^}?Bn[4X@Bn L!?~ B?B MAP2K1;MEF2DChsa00410Cbeta-Alanine metabolismC?@?CnD?CSs3R @ChVo?~ C? CACADMDhsa00640DPropanoate metabolismD@@?DO=?DN @DR}I?~ D? DACADMEhsa04510EFocal adhesionEh@@EM?E"g?E?~ E?EMAP2K1;CCND1;LAMB2Fhsa04725FCholinergic synapseF\@@F{l0?FElVj@F=hHpN?~ F?F MAP2K1;GNG5Ghsa041301G)SNARE interactions in vesicular transportGA@?G|A?G @GLC|?~ G?GSNAP29Hhsa04724HGlutamatergic synapseH\@@H]`zI?HEG @H^쒸?~ H?H GNG5;DLG4Ihsa05206IMicroRNAs in cancerIr@@I:`@Iʒz?IiY/?~ I? IMAP2K1;MCL1;CDKN2A;CCND1Jhsa05020JPrion diseasesJA@?Jsmp~?JiLtսC @J?~ J?JMAP2K1Khsa04919)K!Thyroid hormone signaling pathwayK]@@Kh+&?K QHܲ?K"?~ K?K MAP2K1;CCND1Lhsa00350LTyrosine metabolismLB@?L5E ?L @LI[P?~ L? LTPOMhsa04110M Cell cycleM_@@M{#*D?MSs3R?MS,D?~ M?M CDKN2A;CCND1Nhsa00380NTryptophan metabolismND@?N TM\G?NeF@N$&?~ N? NINMTOhsa04926!ORelaxin signaling pathwayO@`@@O&z?O* 9H?O>"?~ O?O MAP2K1;GNG5Phsa046501P)Natural killer cell mediated cytotoxicityP``@@P+WJ_=?P?P{~Z=?~ P?P MAP2K1;IFNA17Qhsa04068QFoxO signaling pathwayQ`@@Q_Ea?Qzٳ=?Q_)h r?~ Q?Q MAP2K1;CCND1Rhsa00071RFatty acid degradationRF@?R/U?RJFn@Rc{?~ R? RACADMShsa02010SABC transportersSF@?S/U?SJFn@Sc{?~ S? SABCA7Thsa03022#TBasal transcription factorsTF@?T:G?T5m@T&?~ T? TGTF2BUhsa04930!UType II diabetes mellitusUG@?UXݞ?U\@Usr=?~ U? USOCS4Vhsa04910!VInsulin signaling pathwayV a@@VfZ?V!3 ?VWx?~ V?V MAP2K1;SOCS4Whsa00270*W"Cysteine and methionine metabolismWG@?WPr-?W0b @W_+t?~ W? WMTRXhsa04340"XHedgehog signaling pathwayXG@?XPr-?X0b @X_+t?~ X? XCCND1Yhsa002802Y*Valine, leucine and isoleucine degradationYH@?Yw\?Yġk&@YĚ{?~ Y? YACADMZhsa01212ZFatty acid metabolismZH@?Zw\?Zġk&@ZĚ{?~ Z? ZACADM[hsa04330[Notch signaling pathway[H@?[w\?[ġk&@[Ě{?~ [? [HES1\hsa046724\,Intestinal immune network for IgA production\H@?\n ߝJ?\*@\#̊Z?~ \? \CCL28]hsa05030]Cocaine addiction]H@?]n ߝJ?]*@]#̊Z?~ ]? ]DLG4^hsa05110!^Vibrio cholerae infection^I@?^@]`3?^{b@^%v?~ ^?^SEC61G_hsa05014+_#Amyotrophic lateral sclerosis (ALS)_I@?_Rg?_:1U@_M#?~ _? _DERL1Dyl` ,a ,b ,c ,d ,e ,`hsa04723,`$Retrograde endocannabinoid signaling`b@@`W6Ǜ?`VK?`w?~ `?` NDUFB6;GNG5ahsa05226aGastric cancerab@@a5(A?a!m<?a=O?~ a?a MAP2K1;CCND1bhsa03460bFanconi anemia pathwaybK@?bh?b^ @b%?~ b? bHES1chsa04921"cOxytocin signaling pathwaycc@@cyI1*?cz0?cEY?~ c?c MAP2K1;CCND1dhsa03010dRibosomed c@@dM?d=wq?d橮F?~ d?dMRPS18C;MRPL35ehsa05150'eStaphylococcus aureus infectioneL@?e{l0?eElVj@e?~ e? eCFH]d=K_8X>  Oh+'0x8@L X dp???QC@ˮ@Q% ՜.+,00 8@ H ]  Table S3  Worksheets  !"#$%&'()*+,-./02345678:;<=>?@Root EntryF@ެ]Book aSummaryInformation(1DocumentSummaryInformation89